InterMune Reports Third Quarter 2008 Financial Results and Business ...(Diseases (AASLD) InterMune presented eig...)

programs, including its lead protease inhibitor for the treatment of

patients chronically infected with the hepatitis C virus (HCV),

ITMN-191. Among the highlights, InterMune reported:

- Median viral kinetic results for ITMN-191 competitive with those

published for other direct antiviral compounds when used in

monotherapy for 14 days in treatment-naive patients chronically

infected with hepatitis C virus (HCV) genotype 1.

- Excellent safety and tolerability for ITMN-191 in all dosage

regimens.

- The in-vitro combination of ITMN-191 with the active moiety of

polymerase inhibitor R7128 (Roche/Pharmasset) in a 14-day replicon

clearance assay and in a 3-week colony formation assay resulted in

clearance of the HCV replicon and reduced or suppressed the emergence

of drug-resistant viral variants. These results suggest that the

combination would likely result in significantly greater antiviral

activity than has been observed with either of these agents in

previous monotherapy trials.

Guidance for 2008 Operating Expenses

InterMune today reiterated its guidance with respect to operating expenses in 2008.

For the year ending December 31, 2008, R&D expense is anticipated to be in a range of approximately $100 to $110 million, net of development cost reimbursements under the Roche collaboration. G&A expense is anticipated to be in a range of approximately $25 to $30 million.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the third quarter and first nine months of 2008, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call
'/>"/>